Zacks Investment Research downgraded shares of Eisai (OTCMKTS:ESALY) from a buy rating to a hold rating in a research report report published on Monday, Zacks.com reports.
According to Zacks, “Eisai Co LTD is involved in the Biotechnology and Drug Industry. Their principle activities are the manufacture and sale of pharmaceutical products. Operations are carried out through the following divisions: Pharmaceuticals: veterinary drugs other food additives, livestock feed and pharmaceutical production systems and equipment. The Group has overseas consolidated subsidiaries in the United States, Canada, the United Kingdom, France, Germany, East Southeast Asia and South and Central America. “
Other research analysts have also issued research reports about the company. Daiwa Capital Markets lowered Eisai from a neutral rating to a sell rating in a research report on Tuesday, September 17th. Jefferies Financial Group began coverage on Eisai in a research report on Tuesday, September 24th. They set a buy rating on the stock. Finally, Citigroup raised Eisai from a sell rating to a neutral rating in a research report on Monday, August 5th. Three research analysts have rated the stock with a sell rating, one has given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Eisai has a consensus rating of Hold and a consensus price target of $79.00.
ESALY traded up $0.13 during trading on Monday, hitting $65.86. 2,417 shares of the stock were exchanged, compared to its average volume of 10,445. The firm has a market capitalization of $19.47 billion, a P/E ratio of 33.10, a PEG ratio of 2.08 and a beta of 0.35. Eisai has a 1-year low of $48.52 and a 1-year high of $90.41. The stock has a fifty day moving average price of $60.27 and a two-hundred day moving average price of $56.30. The company has a quick ratio of 1.66, a current ratio of 1.91 and a debt-to-equity ratio of 0.14.
Eisai (OTCMKTS:ESALY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.59 by ($0.42). The firm had revenue of $1.35 billion for the quarter. Eisai had a return on equity of 9.07% and a net margin of 9.10%. Analysts predict that Eisai will post 2.59 EPS for the current year.
Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.
Further Reading: Are sell-side analysts objective?
Get a free copy of the Zacks research report on Eisai (ESALY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.